Trial Profile
A Non-randomized, Open-label Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) Progressing After Prior Therapy With Tyrosine Kinase Inhibitors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Jun 2021
Price :
$35
*
At a glance
- Drugs Regorafenib (Primary) ; Sunitinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Adverse reactions
- Acronyms SURE
- 19 May 2021 Status changed from active, no longer recruiting to completed.
- 20 Apr 2021 Planned End Date changed from 1 May 2021 to 1 Jun 2021.
- 17 Aug 2020 Planned End Date changed from 1 May 2020 to 1 May 2021.